Recent Articles:
Increased Investment in Stem Cell Technologies Drives Stem Cell Research Market
Stem cell research is a promising area of biotechnology, which holds tremendous potential in rendering a new approach to the treatment of various degenerative diseases. The area deals with employing regenerative stem cells for the
Teva Representative Joins Mesoblast’s Board of Directors
Global regenerative medicine company Mesoblast Limited (asx:MSB) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, as a non-executive Director of Mesoblast, effective immediately. Dr Weiner
NeuroMetrix (NURO): An Attractive Diabetes Franchise but Significantly Undervalued
NeuroMetrix Inc. (NASDAQ: NURO), is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. Diabetes
Pressure BioSciences (PBIO) Technology In-Depth
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ:
Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer
Cellceutix Corporation (CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers), is pleased to announce that Syracuse University’s legendary men’s basketball
Pressure BioSciences (PBIO) Announces Strategic Partnership with LEAP Technologies
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and
Alliance for Regenerative Medicine Holds Clinical Outlooks for Regenerative Medicine Meeting
The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced it will hold a conference titled, Clinical Outlooks for Regenerative Medicine 2012, in partnership with Harvard
Preventing the Problem Before it Occurs – Athersys Meets with FDA to Discuss Novel Approach to Suppressing Graft Versus Host Disease in Leukemia and other Cancer Patients
Graft versus Host Disease (GvHD) is an area of great unmet medical that represents a significant risk to cancer patients throughout the world. The condition occurs when patients receive a bone marrow transplant following radiation
Shire Delivers Strong Financial Results
Shire plc (PINK: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2012. The Non GAAP financial measures included within this release are explained on page 21, and are
Alliance for Regenerative Medicine News
The Alliance for Regenerative Medicine, an international organization representing interests of the regenerative medicine community, recently released their most recent newsletter containing the latest industry news and events. Please follow the link below to view
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com
TheStreetBeat.com is pleased to announce the latest installment of its CEO Interview Series. A two-part interview will begin airing today featuring a question and answer session with Cellceutix Corporation(CTIX.OB) Chief Executive Officer Leo Ehrlich. Cellceutix, a biopharmaceutical company
ALR Technologies (ALRT) Taglich Brothers Analyst Report in PowerPoint
ALR Technologies Inc. (OTCBB: ALRT), developer of the FDA-cleared Health-e-Connect (HeC) system to monitor patient compliance, operating in the same industry as other companies in the diabetes testing space like Abbott Laboratories (NYSE: ABT) and